Infinitopes
Empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
* | £12.8m | Seed | |
| Total Funding | 000k | ||
Related Content
Infinitopes is a biotechnology company, spun out from Oxford University and supported by Cancer Research UK, that specializes in the development of cancer vaccines. The company utilizes its proprietary 'Precision Immunomics' platform, which integrates artificial intelligence and machine learning, to identify optimal tumor antigens for vaccine development. This technology aims to create highly targeted and immunologically durable treatments.
The company's primary focus is on creating 'off-the-shelf' cancer vaccines designed to prevent metastases. Its lead candidate, ITOP1, is currently advancing through clinical trials. The business operates within the biotech and healthcare sectors, with its primary clients being in the oncology field. The business model is centered on the research, development, and subsequent commercialization of its vaccine candidates, a process that involves significant investment in clinical trials and regulatory approval.
Infinitopes was founded by a team of specialists in oncology, immunology, and vaccinology. The company has successfully raised capital through seed financing to fund its ongoing research and development efforts.
Keywords: cancer vaccines, precision immunomics, oncology, biotechnology, antigen discovery, immunotherapy, clinical trials, Oxford University spinout, AI in healthcare, metastasis prevention